Cellkey
The AI engine Fit Assessment
BetaThe company effectively leverages machine learning for glycopeptide analysis, enabling pattern discovery and expanding therapeutics while focusing on biomarker identification.
Blurb
CellKey is an AI-based glycopeptide analysis solution that provides protein and glycoprotein analysis and biomarker research services.
HQ Location
South Korea
Founded
2019
Employees
11 - 50
Total funding raised
Not available
Last Funding Event
Seed, February 28, 2022
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Biomarker Identification
Developer of AI-based integrated glycopeptide analysis platform intended to develop biotechnologies that contribute towards prolonging human lives. The company utilizes artificial intelligence and machine learning to diagnose and treat life-threatening diseases by combining unique glycoprotein analysis, helping health workers to predict various diseases and qualitatively and quantitatively analyze the type and location of glycoprotein.